Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Mutations in KIT and TET2 are implicated in myeloid malignancies.
• TET2 loss contributes to aberrant cell signaling and impaired differentiation.

Purpose of the Study:

• To investigate the molecular mechanisms by which TET2 loss drives myeloid malignancies.
• To identify potential therapeutic strategies for TET2-mutated cancers.

Main Methods:

• Utilized RNA-sequencing (RNA-Seq) to analyze gene expression in Tet2-/- cells.
• Employed a mouse model mimicking human TET2-mutated myeloid neoplasms.
• Assessed the efficacy of PI3K inhibitors, ascorbic acid, and hypomethylating agents.

Main Results:

• TET2 loss leads to PI3K pathway activation, increased proliferation, and a hyperactive c-Myc signature.
• Impaired mast cell maturation due to dysregulated Mitf and Cebpa expression was observed.
• PI3K inhibition, ascorbic acid, and 5-azacytidine restored normal cellular processes.
• A mouse model developed aggressive neoplasms (AHNMD) responsive to PI3K inhibition.

Conclusions:

• Targeting PI3K signaling, alongside ascorbic acid and hypomethylating agents, shows therapeutic potential for TET2 and KIT mutations.
• These findings offer a basis for developing novel treatment strategies for myeloid malignancies.